Peptide Schedule
Cartalax4 residuesAEDPEach bubble = one amino acid. Size = residue mass. Color = chemical class.Cartalax
Benefits
About Cartalax
Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp (AED), developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It's derived from sequences found in the alpha-1 chain of type XI collagen, a structural protein concentrated in cartilage tissue. In preclinical models, Cartalax has shown the ability to stimulate chondrocyte proliferation in cartilage tissue from both young and old rats. Studies report an 18-38% increase in cartilage area index, alongside upregulation of PCNA (a proliferation marker) and downregulation of p53 (a pro-apoptotic signal). The peptide also appears to inhibit MMP-9 synthesis, which could help preserve extracellular matrix integrity during aging. A 2023 study examined the AED peptide's effect on chondrogenic differentiation of human mesenchymal stem cells during replicative aging. At concentrations of 200 ng/mL, Cartalax activated genes and proteins associated with cartilage formation in aging stem cells, suggesting potential relevance to osteoarthritis research. All current evidence is preclinical, and Western research on this specific peptide remains very limited.
Who Should Consider Cartalax
- Adults over 40 with age-related cartilage degeneration concerns
- Researchers studying Khavinson bioregulator peptides and cartilage biology
- Those exploring adjunct approaches to osteoarthritis management (no clinical proof)
How Cartalax Works
Cartalax is proposed to act through Khavinson's peptide bioregulation mechanism, where short peptides penetrate cell nuclei and bind to specific DNA sequences in gene promoter regions. The tripeptide sequence Ala-Glu-Asp matches a motif in the alpha-1 chain of type XI collagen, and it's thought to selectively interact with cartilage-related genes. In chondrocyte culture models, Cartalax upregulates PCNA and Ki-67, driving cell division. It simultaneously reduces p53 and caspase-3 — both pro-apoptotic signals — creating a net pro-survival, pro-proliferative state in cartilage tissue. The peptide also increases SIRT-1 and SIRT-6 expression, sirtuins involved in DNA repair and cellular stress resistance. On the extracellular matrix side, Cartalax inhibits MMP-9, an enzyme that degrades collagen and proteoglycans.
What to Expect
No noticeable effects expected. Bioregulator peptides are theorized to work at the gene expression level, which takes time to produce measurable changes.
Some anecdotal reports mention reduced joint stiffness. These early reports are not backed by clinical data and may reflect placebo response.
If the bioregulator theory holds, gene expression changes related to cartilage maintenance should be established. No objective human outcome data exists.
Khavinson theory proposes that effects persist after stopping, as epigenetic changes stabilize. This claim is based on animal and cell culture data.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Synthetic tripeptide bioregulator (Ala-Glu-Asp) developed by Khavinson. Targets cartilage tissue and chondrocyte gene expression. Taken orally as capsules — no reconstitution required. Dosing is based on Russian bioregulator protocols; there are no Western clinical trials or formal PK studies.
How to Inject Cartalax
Take capsules orally with water, typically in the morning on an empty stomach or 30 minutes before a meal. No reconstitution or injection required. Standard protocols use 1-2 capsules (10-20 mg) daily for 30 days.
Cycling Protocol
Standard Russian bioregulator cycling protocol: 30 days on, 2-3 months off. Some protocols recommend repeating 2-3 cycles per year.
Pharmacokinetics
Source: Estimated from tripeptide class pharmacokinetics. No direct PK study exists for Cartalax (AED).
Loading the interactive decay curve.
Side Effects
No adverse effects have been documented in preclinical studies or anecdotal reports. However, the safety dataset is extremely small and consists entirely of in vitro and animal data. No controlled human safety trials exist.
Contraindications
- Pregnancy or breastfeeding (no safety data available)
- Known hypersensitivity to alanine, glutamic acid, or aspartic acid
- Active malignancy involving cartilage or bone (theoretical concern given proliferative effects)
- Children and adolescents (not studied in any population under 18)
Drug Interactions
- NSAIDs — unknown interaction; both target inflammatory/matrix pathways in joints
- Other chondroprotective agents (glucosamine, chondroitin) — no interaction data; additive effects are speculative
- No formal drug interaction studies have been conducted for Cartalax
Storage & Stability
Molecular Profile
Related Peptides
References
- Peptide Regulation of Chondrogenic Stem Cell Differentiation (Int J Mol Sci 2023)PubMed 37176122
- The Influence of Peptides on Chondrogenic Differentiation of Human MSCs During Replicative AgingPubMed 37782646
- Effect of Peptide Regulators on Structural and Functional Status of Bone Tissue in Ageing RatsPubMed 18306703
- Peptide Regulation of Gene Expression: A Systematic Review (Molecules 2021)PubMed 34834147
- Peptide Bioregulators: The New Class of Geroprotectors (Adv Gerontol 2013)PubMed 24003726